Tivantinib inhibits the VEGF signaling pathway and induces apoptosis in gastric cancer cells with c-MET or VEGFA amplification
Authors:
- 2 May 2020
- journal article
- research article
- Published by Springer Nature in Investigational New Drugs
- Vol. 38 (6) , 1633-1640
Abstract
Summary Tivantinib has been described as a selective inhibitor of c-Met and is being studied in various types of cancer. In this study, we evaluated the effects of tivantinib on the suppression of gastric cancer (GC) cell migration and apoptosis. We also examined the mechanism of action of tivantinib by oncogenic pathway analysis. We applied an RNA-sequencing approach in 34 GC patients to identify oncogenes that are differentially expressed in GC tissues. To examine the inhibitory effect of tivantinib on GC cells, we conducted apoptosis analysis using an annexin V-APC/PI apoptosis detection kit and trans-well migration assay with human GC cell lines. For oncogenic pathway analysis, Western blot and quantitative real-time PCR analysis were used to detect the expression of proteins and genes before and after tivantinib exposure. In the RNA-sequencing analysis of 34 GC patients, c-Met and VEGFA genes were expressed and positively correlated with each other. Cell migration and apoptosis analysis demonstrated that tivantinib induced the best inhibition effect in SNU620, MKN45 (carries VEGFB mutation), AGS, and MKN28 cells, but not in KATO III (carries VEGFB and VEGFC mutations) cells. Oncogenic pathway analysis showed that tivantinib, in addition to c-Met signaling pathway inhibition, also inhibits VEGF signaling and MYC expression in VEGFA-expressing GC cells. We found that tivantinib has anti-cancer activity not only in GC cells overexpressing c-Met but also in non-c-Met GC cells by inhibition of the VEGF signaling pathway.Keywords
Funding Information
- Ministry of Health and Welfare (HA17C0054)
- Ministry of Food and Drug Safety of Korea (18183MFDS491)
- Korean Ministry of Science and ICT (NRF-2017R1A2B4005055)
This publication has 16 references indexed in Scilit:
- Tivantinib induces G2/M arrest and apoptosis by disrupting tubulin polymerization in hepatocellular carcinomaJournal of Experimental & Clinical Cancer Research, 2015
- Tivantinib (ARQ 197) efficacy is independent of MET inhibition in non‐small‐cell lung cancer cell linesMolecular Oncology, 2014
- The Met receptor tyrosine kinase: A key player in oncogenesis and drug resistancePharmacology & Therapeutics, 2014
- A phase II trial of a selective c-Met inhibitor tivantinib (ARQ 197) monotherapy as a second- or third-line therapy in the patients with metastatic gastric cancerInvestigational New Drugs, 2013
- Cytotoxic Activity of Tivantinib (ARQ 197) Is Not Due Solely to c-MET InhibitionCancer Research, 2013
- Tivantinib (ARQ197) Displays Cytotoxic Activity That Is Independent of Its Ability to Bind METClinical Cancer Research, 2013
- Targeting MET in cancer: rationale and progressNature Reviews Cancer, 2012
- Genetic Activation of the MET Pathway and Prognosis of Patients With High-Risk, Radically Resected Gastric CancerJournal of Clinical Oncology, 2011
- Phase I Trial of a Selective c-MET Inhibitor ARQ 197 Incorporating Proof of Mechanism Pharmacodynamic StudiesJournal of Clinical Oncology, 2011
- ARQ 197, a Novel and Selective Inhibitor of the Human c-Met Receptor Tyrosine Kinase with Antitumor ActivityMolecular Cancer Therapeutics, 2010